Tempus, a leader in artificial intelligence and precision medicine, today announced that the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through the use of real-world data. The Tempus+ community of researchers already includes over 30 medical centers that are leveraging the program to advance its research.

Tempus+ is creating a sustainable and secure infrastructure to collect and analyze the data required to foster research that can inform the future of clinical care. Researchers at UNC Lineberger now have access to Tempus’ library of more than six million de-identified research records through the company’s data analytics platform, Lens, to identify patterns and insights, define and test their hypotheses, and eventually investigate and potentially publish their research. 

“UNC Lineberger has been a great partner in the vision of Tempus+, using our real-world data to explore research questions,” said Mike Thompson, MD, PhD, Vice President of Clinical Partnerships at Tempus. “We appreciate their knowledge and expertise in cancer biology and clinical care, and we hope to continue collaborations in our working groups to move cancer care forward.”

“At UNC Lineberger, we look forward to working with the Tempus+ community to answer practical clinical and translational questions that cannot readily be addressed by data from a single institution,” said Jason D. Merker, MD, PhD, Director of Cancer Molecular Pathology and Co-Director of the Translational Genomics Laboratory at UNC Lineberger. “This use of broad, existing real-world data and evidence has the potential to further inform the development, validation, and application of biomarkers across diverse patient populations.”

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.